EZH2 and neoplasm: Currently, therapeutic decisions are rarely based on molecular or immune profiling, yet emerging evidence suggests that factors such as EZH2 mutations, TP53 alterations, CD20 expression levels, and the immune composition of the tumor microenvironment could inform the optimal use of monoclonal antibodies.